Druggable lipid signaling pathways / Yasuyuki Kihara, editor.
Kihara, Yasuyuki.
2020
QP751
Available Online

Linked e-resources

Linked Resource
Online Access

Details

Title
Druggable lipid signaling pathways / Yasuyuki Kihara, editor.
ISBN
9783030506216 (electronic book)
3030506215 (electronic book)
3030506207
9783030506209
DOI
https://doi.org/10.1007/978-3-030-50621-6
Publication Details
Cham, Switzerland : Springer, 2020.
Language
English
Description
1 online resource
Item Number
10.1007/978-3-030-50621-6 doi
10.1007/978-3-030-50
Call Number
QP751
Dewey Decimal Classification
612/.01577
611.01816
Summary
This edited work presents a series of reviews focusing on Druggable Lipid Signaling Pathways. It enables researchers in both academic institutions and industry as well as physicians to understand historical aspects of lipid signaling and future directions of drug discovery targeting lipid signaling pathways. This book provides 9 pathways including acyltransferases, prostanoids, leukotrienes, epoxy fatty acids, sphingolipids, lysophospholipids, endocannabinoids, phosphoinositides, and lipid GPCRs. Readers will discover the importance of each lipid signaling pathway that contributes to broad range of diseases including neurological and neuropsychiatric diseases, pain, metabolic syndromes, cardiovascular diseases, cancer, dermatological diseases, fibrosis, inflammation, etc. Also, readers will recognize that many drugs targeting lipid signaling have been clinically used. Drugs currently under development are also discussed in each chapter, which includes some information about clinical trials and strategic drug designs.
Note
Includes index.
Access Note
Access limited to authorized users.
Added Author
Kihara, Yasuyuki.
Series
Advances in experimental medicine and biology ; v. 1274.
Available in Other Form
Print version: 9783030506209
Linked Resources
Online Access
Record Appears in
Online Resources > Ebooks
All Resources
Preface
Introduction of Druggable Lipid Signaling Pathway
Biosynthetic Enzymes of Membrane Glycerophospholipid Diversity as Therapeutic Targets for Drug Development
Druggable Prostanoid Pathway
Targeting Leukotrienes as a Therapeutic Strategy to Prevent Comorbidities Associated with Metabolic Stress
Epoxy Fatty Acids are Promising Targets for Treatment of Pain, Cardiovascular Disease and Other Indications Characterized by Mitochondrial Dysfunction, Endoplasmic Stress and Inflammation
Druggable Sphingolipid Pathway
Druggable Lysophospholipid Pathway
Druggable targets in endocannabinoid signaling
Drugging the phosphoinositide 3-kinase (PI3K) and phosphatidylinositol 4-kinase (PI4K) family of enzymes for treatment of cancer, immune disorders, and viral/parasitic infections
Druggable Lipid GPCRs: Past, Present, and Prospects.

Browse Subjects

Show more subjects...

Statistics

from
to
Export